BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12130525)

  • 1. Complete remission through blast cell differentiation in PLZF/RARalpha-positive acute promyelocytic leukemia: in vitro and in vivo studies.
    Petti MC; Fazi F; Gentile M; Diverio D; De Fabritiis P; De Propris MS; Fiorini R; Spiriti MA; Padula F; Pelicci PG; Nervi C; Lo Coco F
    Blood; 2002 Aug; 100(3):1065-7. PubMed ID: 12130525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo.
    Zhou DC; Kim SH; Ding W; Schultz C; Warrell RP; Gallagher RE
    Blood; 2002 Feb; 99(4):1356-63. PubMed ID: 11830487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 8-CPT-cAMP/all-trans retinoic acid targets t(11;17) acute promyelocytic leukemia through enhanced cell differentiation and PLZF/RARα degradation.
    Jiao B; Ren ZH; Liu P; Chen LJ; Shi JY; Dong Y; Ablain J; Shi L; Gao L; Hu JP; Ren RB; de Thé H; Chen Z; Chen SJ
    Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3495-500. PubMed ID: 23382200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
    Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG
    Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy.
    Ding W; Li YP; Nobile LM; Grills G; Carrera I; Paietta E; Tallman MS; Wiernik PH; Gallagher RE
    Blood; 1998 Aug; 92(4):1172-83. PubMed ID: 9694705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [hCG-PLZF-RARalpha/hCG-RARalpha-PLZF transgenic mice developing into leukemia].
    Chen LJ; Dong Y; Chen SY; Zhang L; Zhou GB; Chen B; Wang L; Chen Z; Chen SJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):924-31. PubMed ID: 16403252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
    Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
    Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid.
    Kitamura K; Hoshi S; Koike M; Kiyoi H; Saito H; Naoe T
    Br J Haematol; 2000 Mar; 108(4):696-702. PubMed ID: 10792271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
    Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse of acute promyelocytic leukemia with PML-RARalpha mutant subclones independent of proximate all-trans retinoic acid selection pressure.
    Gallagher RE; Schachter-Tokarz EL; Zhou DC; Ding W; Kim SH; Sankoorikal BJ; Bi W; Livak KJ; Slack JL; Willman CL
    Leukemia; 2006 Apr; 20(4):556-62. PubMed ID: 16437139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study.
    Visani G; Buonamici S; Malagola M; Isidori A; Piccaluga PP; Martinelli G; Ottaviani E; Grafone T; Baccarani M; Tura S
    Leukemia; 2001 Nov; 15(11):1696-700. PubMed ID: 11681409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favourable outcome in an APL patient with PLZF/RARalpha fusion gene: quantitative real-time RT-PCR confirms molecular response.
    Cassinat B; Guillemot I; Moluçon-Chabrot C; Zassadowski F; Fenaux P; Tournilhac O; Chomienne C
    Haematologica; 2006 Dec; 91(12 Suppl):ECR58. PubMed ID: 17194664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial.
    Diverio D; Rossi V; Avvisati G; De Santis S; Pistilli A; Pane F; Saglio G; Martinelli G; Petti MC; Santoro A; Pelicci PG; Mandelli F; Biondi A; Lo Coco F
    Blood; 1998 Aug; 92(3):784-9. PubMed ID: 9680345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute promyelocytic leukemia with a PLZF-RARalpha fusion protein.
    Jansen JH; Löwenberg B
    Semin Hematol; 2001 Jan; 38(1):37-41. PubMed ID: 11172538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha.
    Cheng GX; Zhu XH; Men XQ; Wang L; Huang QH; Jin XL; Xiong SM; Zhu J; Guo WM; Chen JQ; Xu SF; So E; Chan LC; Waxman S; Zelent A; Chen GQ; Dong S; Liu JX; Chen SJ
    Proc Natl Acad Sci U S A; 1999 May; 96(11):6318-23. PubMed ID: 10339585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells.
    Côté S; Rosenauer A; Bianchini A; Seiter K; Vandewiele J; Nervi C; Miller WH
    Blood; 2002 Oct; 100(7):2586-96. PubMed ID: 12239173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinico-biological features and prognostic significance of PML/RARalpha isoforms in adult patients with acute promyelocytic leukemia treated with all trans retinoic acid (ATRA) and chemotherapy.
    Gupta V; Yib QL; Brandwein J; Chun K; Lipton JH; Messner H; Schuh AC; Wells RA; Minden MD; Kamel-Reidc S
    Leuk Lymphoma; 2004 Mar; 45(3):469-80. PubMed ID: 15160908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80.
    Takeuchi M; Yano T; Omoto E; Takahashi K; Kibata M; Shudo K; Harada M; Ueda R; Ohno R
    Leuk Lymphoma; 1998 Nov; 31(5-6):441-51. PubMed ID: 9922035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute promyelocytic leukemia and variant fusion proteins: PLZF-RARα fusion protein at a glance.
    Hussain L; Maimaitiyiming Y; Islam K; Naranmandura H
    Semin Oncol; 2019 Apr; 46(2):133-144. PubMed ID: 31126665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcription therapy for acute promyelocytic leukaemia.
    Douer D
    Expert Opin Investig Drugs; 2000 Feb; 9(2):329-46. PubMed ID: 11060680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.